Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Has US Rituximab Nod - But No RA Indication

Riabni Biosimilar Rival To Rituxan Seeks To Compete With Price Discount

Executive Summary

Amgen has received FDA approval and revealed launch plans for its Riabni rituximab rival to Rituxan, setting a price discount in line with Pfizer’s Ruxience version. However, the biosimilar has not been approved for the rheumatoid arthritis indication that is enjoyed by Teva and Celltrion’s higher-priced Truxima version.

You may also be interested in...



Amgen Launches Rituxan Rival In US

Amgen has announced the launch of its biosimilar version of Rituxan (rituximab), Riabni, in the US market, further expanding the firm’s oncology biosimilars portfolio.

Henlius Seeks To Add RA Indication To Chinese Rituximab

Shanghai Henlius Biotech has filed with China’s NMPA to add a rheumatoid arthritis indication to its HLX01 approved rituximab biosimilar, despite the originator not being approved for RA in China.

What’s Next? Five Things To Look Out For In January

A third biosimilar to Genentech’s Rituxan is set to hit the US this month, as players begin to publish full-year financial results encompassing a remarkable year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel